SYI Synvista Therapeutics,

LOS ANGELES, Sept. 15 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Synvista Therapeutics, Inc. (AMEX:SYI) and maintains its $4.46 target price. Ross Silver, Director of Research of Vista Partners stated, "Several near term catalysts that investors should be aware of are the progression of the Haptoglobin diagnostic test - mainly the IDE meeting and its first sales in 2009. Recent positive news pertaining to the speed and efficacy of the diagnostic test kit should reduce some pipeline risk and increase the stock price." To view the FREE report on Synvista, please visit the Vista Partners website at http://www.vistap.com/ and click on the download research icon. About Vista Partners: Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com/. About Synvista Therapeutics, Inc.: Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing Alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. Contact: Vista Partners LLC Jorden Lampos 310-744-5268 http://www.vistap.com/ DATASOURCE: Vista Partners CONTACT: Jorden Lampos of Vista Partners LLC, +1-310-744-5268, Web site: http://www.vistap.com/

Copyright